Diabetes

Episode 13 assesses the evolution of MASH, how it’s managed by pharmacists, and how it provides another avenue for improving cardiometabolic disease.

A study finds treated diabetes prevalence climbs steadily for 5 years after antipsychotic start, even with brief exposure.

Community pharmacists use medication therapy management and point-of-care testing for improved hemoglobin A1C, BP, and lipid assessment as well as adherence.

The rapid-acting insulin aspart biosimilar adds a third interchangeable option to NovoLog, with implications for pharmacy dispensing and counseling.

Large trial emulation study finds a 21% reduction in 3-year fracture risk compared with DPP-4 inhibitors, independent of weight loss or glycemic changes.

Managing diabetes has shifted from reactive monitoring to a proactive, technology-driven standard of care that emphasizes real-time data and personalized treatment.

Positive results from TRIUMPH-2 and TRIUMPH-3 bring retatrutide's obesity program to 5 successful trials, with Lilly planning to submit in early 2027.

A secret shopper study finds most are still compounding semaglutide and tirzepatide with additives, often through suppliers lacking sterile compounding licenses.

Emerging data show glucagon-like peptide-1 receptor agonists may raise the risk of certain autoimmune diseases compared with other diabetes drugs.

A new analysis shows that socioeconomic status shrinks type 2 diabetes risk far more for nonHispanic white and Asian Americans than for nonHispanic Black and Hispanic Americans.

New case-control study finds that patients with type 2 diabetes and more severe depressive symptoms show higher cortisol, higher hemoglobin A1C, and lower insulin.

Data show bone density and lean mass losses can be clinically meaningful, but case reports point to resistance training as effective countermeasures.

The filing acceptance marks a step toward lower-cost alternatives to Mounjaro and Zepbound.

Episode 12 explores recent updates from the 2026 ADA Scientific Sessions, highlighting for pharmacists which technologies are making waves in the diabetes space right now.

Bryan Wheeler, PharmD, discusses how the Medicare GLP-1 Bridge program works and what it means for independent pharmacy operations.

Pharmacists leverage CGM and automated insulin delivery to personalize diabetes care, prevent errors, and expand equitable access to technology.

A drug already used to protect the kidneys may now offer a broader shield.

Diabetes technology shifts to continuous glucose monitoring, automated insulin delivery, and connected pens, empowering pharmacists to guide safer care.

The ACTIV-6 trial suggests early metformin may halve clinician-diagnosed long COVID risk, offering a low-cost option pharmacists can apply safely.

This decision marks a milestone in clinical pharmacy as it targets the underlying autoimmune destruction of pancreatic beta cells.

FDA clears first OTC CGM for children 2 years and older, expanding tracking beyond prescriptions for pediatric populations.

Pharmacists close these gaps through screening and prevention for patients.

Once-weekly mazdutide drives approximately 17% weight loss in Chinese adults with obesity, offering a dual GLP-1/glucagon metabolic option.

Medicare’s $35 insulin cap cuts cost swings, boosts adherence for high-burden patients, and highlights pharmacists’ role in preventing rationing.

New 9-year data shows some high-risk prediabetes patients progress to type 2 diabetes despite 8% weight loss.